YI
Rohto Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DE-130 (Etrasimod) | Ulcerative Colitis | Phase 3 |
| DE-126 (Finerenone) | Diabetic Kidney Disease / Chronic Kidney Disease with Type 2 Diabetes | Filed |
| DE-122 (Carotegrast methyl) | Ulcerative Colitis | Phase 3 |
| DE-120 (Ciclosporin ophthalmic gel) | Dry Eye Disease | Phase 3 |
| RV-001 | Retinal Diseases (e.g., AMD, DR) | Preclinical |
| Rohto Zi: / Rohto C Cube: | Eye Fatigue, Dry Eye, Allergic Conjunctivitis | Commercial |
| Hada Labo | Skin Moisturization & Care | Commercial |
Leadership Team at Rohto Pharmaceutical
MS
Masashi Sugimoto
Representative Director, President & CEO
TY
Takeshi Yoshida
Director, Senior Managing Executive Officer
HY
Hiroshi Yamaguchi
Director, Senior Managing Executive Officer
KA
Kazunori Araki
Director, Managing Executive Officer
YO
Yasuhiko Oshima
Director, Managing Executive Officer
SO
Shinji Oshima
Director
YO
Yoshihiro Oka
Director
YK
Yoshiko Kita
Director
TK
Takashi Kondo
Corporate Auditor
YI
Yoshihisa Inoue
Corporate Auditor